Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.43 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402336 | 1.00 | P2RX7 (0.48) | P2RX7TRPV1KCNJ11FFAR4GPR139 | |
| SCHEMBL6406446 | 0.82 | P2RX7 (0.69) | P2RX7KCNJ11LMNA | |
| SCHEMBL6406444 | 0.82 | P2RX7 (0.69) | P2RX7KCNJ11LMNA | |
| SCHEMBL4684181 | 0.76 | KCNJ11 (0.69) | KCNJ11 | |
| SCHEMBL4684178 | 0.76 | KCNJ11 (0.69) | KCNJ11 | |
| SCHEMBL4679954 | 0.75 | KCNJ11 (0.59) | P2RX7KCNJ11 | |
| SCHEMBL4679952 | 0.75 | KCNJ11 (0.59) | P2RX7KCNJ11 | |
| SCHEMBL6405690 | 0.75 | P2RX7 (0.54) | P2RX7TRPV1ALDH1A1LMNAMAPT | |
| SCHEMBL6405693 | 0.75 | P2RX7 (0.54) | P2RX7TRPV1ALDH1A1LMNAMAPT | |
| SCHEMBL4681863 | 0.74 | KCNJ11 (0.56) | P2RX7KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | claimed |
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | P2RX3, P2RX7, P2RX1 | P2RX7 2/4885TRPV1 15/4885KCNJ11 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.